Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)
Year: 2018
Type: article
Abstract: Background: Ensartinib is a potent ALK small molecule tyrosine kinase inhibitor (TKI). It has shown efficacy in intracranial tumor models. The activity of ensartinib is being evaluated in an ongoing phase 2 study of ALK positive NSCLC patients (pts). As progression due to growth of pre-existing brain metastases (BrM) or development of new BrM is a common mechanism of treatment resistance, we examined the clinical intracranial activity of ensartinib in pts with known BrM (target and/or non-target) at baseline or subsequent central nervous system (CNS) progression.
Source: Annals of Oncology
Institutions: Stanford Medicine, Stanford University, City Of Hope National Medical Center, City of Hope, University of Wisconsin–Madison, Moores Cancer Center, The University of Texas MD Anderson Cancer Center, New York University, University of California San Diego, Dana-Farber Cancer Institute, Providence Portland Medical Center, Washington University in St. Louis, Walter Reed National Military Medical Center, Xcovery (United States), Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2895826082